Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...168169170171172173174175176177178...208209»
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Preclinical, Journal, PD(L)-1 Biomarker, IO Biomarker:  Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models. (Pubmed Central) -  Aug 18, 2020   
    PD-1 mAb or apatinib alone and combination therapy were used...Thus, anti-angiogenesis therapy could improve the efficiency of ICI in VEGFA-overexpressed tumors. Revealing whether there is hypervascularization in tumor tissues may help to clarify the adoption of anti-angiogenesis and ICI combination therapy or ICI monotherapy in cancer treatment.
  • ||||||||||  AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
    Trial completion date:  A Phase II Study in Patients With Alopecia Areata (clinicaltrials.gov) -  Aug 17, 2020   
    P2,  N=80, Recruiting, 
    Prospective randomized controlled clinical trial is warranted. Trial completion date: Nov 2021 --> Jul 2021
  • ||||||||||  BP102 (bevacizumab biosimilar) / Jiangsu Hengrui Medicine
    [VIRTUAL] Effects of the STAT3 inhibitors on senescent tumour cells () -  Aug 15, 2020 - Abstract #ITOCI2020ITOC-I_89;    
    Results We have previously demonstrated that docetaxelinduced senescence in the TC-1 and TRAMP-C2 murine tumour cell lines, which was proved by in vitro (detection of increased p21 expression, positive beta-galactosidase staining, and the typical SASP capable to induce ‘bystander’ senescence), and in vivo experiments, using C57BL/6 mice [1]...This work was supported by the research grant No. NV18-05-00562 provided by the Grant Agency of the Ministry of Health of the Czech Republic.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg., plinabulin (BPI 2358) / BeyondSpring
    Journal:  Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies. (Pubmed Central) -  Aug 14, 2020   
    Results support the clinical testing of plinabulin as a non-G-CSF-based treatment for CIN associated with chemotherapies of different mechanisms. Results also support HSPC as a focal point for future mechanism-of-action work aimed at understanding the ability of plinabulin to reduce this serious side effect of cytotoxic therapy in cancer patients.
  • ||||||||||  AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
    Trial completion date, Trial primary completion date:  OPAL2: A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease (clinicaltrials.gov) -  Aug 13, 2020   
    P2,  N=144, Recruiting, 
    Pyrotinib exhibited good efficacy in HER2-positive local advanced and metastatic breast cancer with manageable toxicity. Trial completion date: Aug 2020 --> Mar 2021 | Trial primary completion date: May 2020 --> Mar 2021
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, doxorubicin hydrochloride / Generic mfg.
    Journal:  Apatinib-induced NF-κB inactivation sensitizes triple-negative breast cancer cells to doxorubicin. (Pubmed Central) -  Aug 11, 2020   
    Moreover, our in vivo results indicate the combination of DOX and apatinib exerted increased antitumor effects on TNBC cell xenograft models. Taken together, our study suggests that apatinib sensitizes TNBC cells to DOX in vitro and in vivo through inactivation of NF-κB signaling pathways, providing a rationale for the combined use of apatinib and DOX in TNBC chemotherapy.
  • ||||||||||  gefitinib / Generic mfg.
    Enrollment change, Trial completion date, Trial primary completion date:  Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance (clinicaltrials.gov) -  Aug 8, 2020   
    P2,  N=100, Recruiting, 
    Taken together, our study suggests that apatinib sensitizes TNBC cells to DOX in vitro and in vivo through inactivation of NF-κB signaling pathways, providing a rationale for the combined use of apatinib and DOX in TNBC chemotherapy. N=300 --> 100 | Trial completion date: Aug 2019 --> Dec 2021 | Trial primary completion date: Aug 2019 --> Oct 2020
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Platinum resistant:  Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer (clinicaltrials.gov) -  Aug 8, 2020   
    P2,  N=1, Terminated, 
    N=300 --> 100 | Trial completion date: Aug 2019 --> Dec 2021 | Trial primary completion date: Aug 2019 --> Oct 2020 N=40 --> 1 | Trial completion date: Jul 2023 --> Jun 2020 | Recruiting --> Terminated | Trial primary completion date: Jul 2021 --> Jun 2020; No patient enter this study.